

AMOXYCILLIN (Oral)

Trade Name	Alphamox® (Viartis) Ospamox® (Novartis)					
Class	Beta lactam antibiotic					
Mechanism of Action	Inhibits bacterial wall synthesis.					
Indications	Indication 1: Chemoprophylaxis for renal anomalies in jaundiced babies or if at risk of jaundice. Indication 2: Nonsystemic infection sensitive to amoxycillin					
Contraindications	Known sensitivity					
Supplied As	Powder for reconstitution to make a 125mg/5mL solution					
Dilution	<table border="1"> <thead> <tr> <th>Water Added</th> <th>Concentration</th> </tr> </thead> <tbody> <tr> <td>See instructions on the bottle</td> <td>125mg/5mL or 250mg/5mL depending on availability</td> </tr> </tbody> </table>		Water Added	Concentration	See instructions on the bottle	125mg/5mL or 250mg/5mL depending on availability
Water Added	Concentration					
See instructions on the bottle	125mg/5mL or 250mg/5mL depending on availability					
Dosage	Indication 1: 50 mg Indication 2: 25mg/kg/dose					
Interval	Indication 1: Daily Indication 2: 12 hourly ≤ 7days age 8 hourly >7days					
Administration	Oral					
Compatible With	N/A					
Incompatible With	N/A					
Monitoring	Nil required					
Stability	Stable for 14 days after reconstitution, shake well before use.					
Storage	Store prepared suspension in the fridge. Dry powder is stored at room temperature.					
Adverse Reactions	Rash, urticaria, hypersensitivity, diarrhoea, altered bowel flora, thrush.					
Metabolism	Mostly excreted unchanged in urine.					
Comments	Shake well before use.					

References	<ol style="list-style-type: none"> 1. Micromedex 2. www.medsafe.govt.nz 3. www.nzf.org.nz 4. Neofax in www.micromedexsolutions.com 5. Starship guidelines www.starship.org.nz www.anmf.org 	
Updated By	<p>P Schmidt, B Robertshawe A Lynn, B Robertshawe A Lynn, B Robertshawe A Lynn, M Wallenstein, B Robertshawe, A Evison A Lynn, B Robertshawe</p>	<p>October 2004 June 2012 (re-order profile), Oct 2013 (oral dilution) May 2020 (review/ update) May 2023 (routine review)</p>